This Kalorama Information report - The World Anesthesia Drug Market - focuses on three primary segments of anesthesia:
Adjunctive Therapies in Anesthesia
The report covers both currently marketed and late stage development anesthesia drugs in detail. Revenues for each segment were generated using dollar and unit sales for each product. Forecasted figures were generated using a combination of projected surgical procedures, patent and exclusivity expirations, pricing trends, new developments and other factors.
The report includes statistical information for surgical procedures, incidence of conditions requiring surgery, and other relevant information. Statistical information is presented as a worldwide overview, with special emphasis on the U.S. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with more than 50 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2009. Historical data was provided for the years 2007 and 2008, with forecast data provided for 2010 through 2014. Compound annual growth rates (CAGRs) are provided for the 2007-2009, 2007-2014 and 2009-2014 periods for each industry segment covered. Competitive analysis is provided for the year 2009 with a projected competitive analysis for 2014. The forecasted market analysis for 2009-2014 was highly influenced by the probability of approval and sales of products in late stage development, product marketing, and demographic trends.
New York, April 5, 2010—Since women have different physiology than men, should we expect that they would react to anesthesia in the same way? Historically most drug development studies have been done on men and the findings applied to women. But women wake up from anesthesia up to twice as fast as men, even after controlling for their lower body weight, and they suffer more severe side effects. This gender difference, which has significant implications for clinical trials, is one of the trends in the dynamic $4.1 billion anesthesia market which pharmaceutical companies will need to address in their drug development strategy, according to The World Anesthesia Drug Market from healthcare market research publisher Kalorama Information.
“Recently there has been a renewed interest in pharmacokinetics—the study of what the body does to a drug, versus what the drug does to the body—and exploring the ways in which men and women react differently to certain drugs,” said Melissa Elder, analyst for Kalorama Information and author of the report. “Research has provided support for this gender variation, and particularly for anesthesia drugs.”
In 1993, the FDA took two important steps to ensure that new drugs are properly evaluated in women. Firstly, the FDA provided formal guidance to drug developers to emphasize its expectation that women will be appropriately represented in clinical studies and that new drug applications will include analyses to identify potential gender differences in drug actions or efficacy. Secondly, the FDA revoked a 1977 policy that excluded most women with childbearing potential from the earliest phases of clinical trials.
Duke University assessed a study in 1999 that found women to be more likely to wake-up from general anesthesia as compared to men. This suggests that women need more anesthesia pound for pound than men during procedures. In addition, Harvard University has done research in the areas of pain and anesthesia that suggest women have lower pain tolerance than men and experience more chronic pain disorders. This may be due to hormonal differences and psychosocial factors. Other studies have also found that women are more sensitive to anesthesia during recovery and tend to have more severe nausea and vomiting than men.
Research has exposed a variety of reasons for the differences in gender response to certain drugs that go beyond women’s lower body weight, and include differences in absorption, metabolizing and elimination of drugs and the effects of liver enzymes and sex hormones. These differences often result in more serious side effects for women than men, more women developing life threatening ventricular arrhythmia after taking a variety of drugs and women waking up faster than men from anesthesia.
“In clinical trials of potential anesthesia products, much closer attention is necessary to ensure that products are safe for both sexes, requiring an equal mix of men and women in trials,” says Elder. “But inclusion alone is not enough—an effort to use data from the trials to discover potential gender differences is also needed.”
The World Anesthesia Drug Market analyzes this market, and provides key information including market data and forecasts, product reviews, trends and issues, and detailed company profiles.
About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.
Search inside this report
Global Site License
Departmental Site License (one location, up to 10 users)